Gorilla Technology (Nasdaq: GRRR) proudly announced CEO Jay Chandan’s nomination for the 2025 Nobel Sustainability Trust Award in “Leadership in Implementation,” spotlighting the company’s global impact in sustainable smart city innovation. The honor underscores Gorilla’s commitment to intelligent, eco-forward infrastructure and its role in transformative initiatives like the O.N.E. Amazon Impact Fund.

NioCorp (Nasdaq: NB) has acquired FEA Materials' scandium alloy manufacturing assets and IP in a move that positions the company to build America’s first vertically integrated scandium supply chain—from mining to finished alloy parts. Once its Elk Creek project is fully operational, NioCorp aims to supply both defense and commercial markets with domestically produced Al-Sc master alloy, capitalizing on Pentagon-backed funding and rising demand for critical minerals.

Jupiter Neurosciences (Nasdaq: JUNS) caps its first year as a public company with major strides on both clinical and commercial fronts, including FDA clearance to launch a Phase 2a trial of JOTROL™ in Parkinson’s disease and the debut of its Nugevia™ consumer line in the $8T longevity market. Backed by strategic, flexible financing and a growing portfolio of neuroprotective innovations, Jupiter heads into 2026 with strong tailwinds and a clear path to long-term value creation.

Greenwich LifeSciences (Nasdaq: GLSI) has surpassed 1,000 patients screened in its global Phase III FLAMINGO-01 trial evaluating GLSI-100, a HER2-targeted immunotherapy to prevent breast cancer recurrence. With 140 active sites across the U.S. and Europe and interest expanding globally, the Company is building strong momentum toward interim analyses and potential efficacy across multiple HLA types in a large, high-risk patient population.